Ratings by Wells Fargo (Derek Archila)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | Q32 Bio Inc. | QTTB | Upgrade | Overweight (Equal Weight) |
11.21 (15.05) |
34.26% | Details | |
| 7/10/2026 | X4 Pharmaceuticals | XFOR | New Coverage | Overweight (N/A) |
3.96 (3.82) |
-3.54% | Details | |
| 6/29/2026 | Viridian Therapeutic | VRDN | Upgrade | Overweight (Equal Weight) |
17.90 (18.03) |
0.73% | Details | |
| 6/15/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/1/2026 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2026 | Cabaletta Bio | CABA | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/15/2026 | Alumis Inc | ALMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2026 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2026 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2026 | Exelixis | EXEL | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/6/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/4/2026 | Alumis Inc | ALMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/1/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 4/17/2026 | Apellis Pharmaceuticals | APLS | Downgrade | Equal Weight (Overweight) |
40.87 (41.03) |
0.39% | Details | |
| 4/17/2026 | Soleno Therapeutics Inc. | SLNO | Downgrade | Equal Weight (Overweight) |
52.57 (53.01) |
0.84% | Details | |
| 4/9/2026 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2026 | Viridian Therapeutic | VRDN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 3/19/2026 | ALX Oncology | ALXO | New Coverage | Overweight (N/A) |
2.15 (2.10) |
-2.33% | Details | |
| 3/18/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2026 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2026 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/17/2026 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/13/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2026 | Exelixis | EXEL | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/11/2026 | Incyte | INCY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/3/2026 | Viridian Therapeutic | VRDN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 1/29/2026 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 1/20/2026 | Incyte | INCY | Downgrade | Equal Weight (Overweight) |
106.21 (117.25) |
10.39% | Details | |
| 1/8/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Monte Rosa Therapeutics | GLUE | Upgrade | Overweight (Equal Weight) |
16.45 (24.56) |
49.3% | Details | |
| 12/12/2025 | Sutro Biopharma | STRO | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 12/9/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/8/2025 | Incyte | INCY | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/8/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2025 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Septerna Inc | SEPN | Upgrade | Overweight (Equal Weight) |
19.24 (33.40) |
73.6% | Details | |
| 11/11/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/11/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 11/6/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/29/2025 | Incyte | INCY | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/23/2025 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/21/2025 | Exelixis | EXEL | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/20/2025 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/15/2025 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Equal Weight) |
23.15 (41.03) |
77.24% | Details | |
| 10/8/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/24/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2025 | C4 Therapeutics | CCCC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2025 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2025 | Soleno Therapeutics Inc. | SLNO | New Coverage | Overweight (N/A) |
66.81 (53.01) |
-20.66% | Details | |
| 8/12/2025 | Sutro Biopharma | STRO | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/12/2025 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (Underweight) |
|
Details | ||
| 8/7/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/7/2025 | Viridian Therapeutic | VRDN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/7/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/6/2025 | Incyte | INCY | Upgrade | Overweight (Equal Weight) |
77.72 (106.21) |
36.66% | Details | |
| 6/26/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/25/2025 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (Underweight) |
|
Details | ||
| 6/17/2025 | Blueprint Medicines | BPMC | Downgrade | Equal Weight (Overweight) |
128.25 (129.46) |
0.94% | Details | |
| 6/3/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2025 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/16/2025 | Septerna Inc | SEPN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/9/2025 | Q32 Bio Inc. | QTTB | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/8/2025 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/2/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/9/2025 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/28/2025 | Septerna Inc | SEPN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/24/2025 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (Underweight) |
|
Details | ||
| 2/24/2025 | Exelixis | EXEL | Downgrade | Equal Weight (Overweight) |
36.85 (55.92) |
51.75% | Details | |
| 2/18/2025 | Septerna Inc | SEPN | Downgrade | Equal Weight (Overweight) |
12.96 (33.40) |
157.72% | Details | |
| 1/30/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2024 | Zymeworks | ZYME | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2024 | C4 Therapeutics | CCCC | Upgrade | Overweight (Equal Weight) |
3.65 (3.69) |
1.1% | Details | |
| 12/19/2024 | Viridian Therapeutic | VRDN | Downgrade | Equal Weight (Overweight) |
18.93 (17.90) |
-5.44% | Details | |
| 12/18/2024 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (N/A) |
|
Details | ||
| 12/11/2024 | Q32 Bio Inc. | QTTB | Downgrade | Equal Weight (Overweight) |
22.67 (11.21) |
-50.55% | Details | |
| 12/2/2024 | Kymera Therapeutics | KYMR | Upgrade | Overweight (Equal Weight) |
46.85 (115.77) |
147.11% | Details | |
| 11/6/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/1/2024 | Zymeworks | ZYME | Downgrade | Equal Weight (Overweight) |
13.70 (17.67) |
28.98% | Details | |
| 10/31/2024 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2024 | Acelyrin Inc | SLRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/1/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2024 | Celldex Therapeutics | CLDX | Upgrade | Overweight (Equal Weight) |
40.96 (35.35) |
-13.7% | Details | |
| 9/11/2024 | Q32 Bio Inc. | QTTB | New Coverage | Overweight (N/A) |
47.96 (15.05) |
-68.62% | Details | |
| 8/12/2024 | Zentalis Pharmaceuticals | ZNTL | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/12/2024 | Ventyx Biosciences Inc | VTYX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Kymera Therapeutics | KYMR | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/12/2024 | Celldex Therapeutics | CLDX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/12/2024 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 7/8/2024 | Acelyrin Inc | SLRN | Upgrade | Overweight (Equal Weight) |
4.06 (2.27) |
-44.09% | Details | |
| 6/18/2024 | Zentalis Pharmaceuticals | ZNTL | Downgrade | Equal Weight (Overweight) |
8.39 (2.71) |
-67.7% | Details | |
| 6/5/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/16/2024 | Sutro Biopharma | STRO | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/15/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | C4 Therapeutics | CCCC | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/9/2024 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/3/2024 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | Acelyrin Inc | SLRN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/12/2024 | Ventyx Biosciences Inc | VTYX | Upgrade | Overweight (Equal Weight) |
8.04 (14.00) |
74.13% | Details | |
| 3/12/2024 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Ventyx Biosciences Inc | VTYX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/29/2024 | Viridian Therapeutic | VRDN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2024 | Celldex Therapeutics | CLDX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/23/2024 | Kymera Therapeutics | KYMR | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/23/2024 | C4 Therapeutics | CCCC | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/16/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2023 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2023 | Arvinas Inc. | ARVN | Upgrade | Overweight (Equal Weight) |
35.43 (8.01) |
-77.39% | Details | |
| 12/14/2023 | Apellis Pharmaceuticals | APLS | Downgrade | Equal Weight (Overweight) |
62.88 (23.15) |
-63.18% | Details | |
| 11/10/2023 | Celldex Therapeutics | CLDX | Upgrade | Equal Weight (Underweight) |
25.78 (35.35) |
37.12% | Details | |
| 11/9/2023 | Arvinas Inc. | ARVN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/2/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2023 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2023 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Equal Weight) |
43.31 (41.03) |
-5.26% | Details | |
| 7/31/2023 | Blueprint Medicines | BPMC | Upgrade | Overweight (Equal Weight) |
63.12 (129.46) |
105.1% | Details | |
| 7/20/2023 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 6/14/2023 | Blueprint Medicines | BPMC | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/16/2023 | Horizon Therapeutics | HZNP | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/5/2023 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/21/2023 | Sutro Biopharma | STRO | New Coverage | Equal Weight (N/A) |
5.22 (23.57) |
351.53% | Details | |
| 3/21/2023 | Zymeworks | ZYME | New Coverage | Overweight (N/A) |
8.36 (24.19) |
189.35% | Details | |
| 1/3/2023 | Blueprint Medicines | BPMC | Upgrade | Equal Weight (Underweight) |
43.00 (129.46) |
201.07% | Details | |
| 1/3/2023 | Arvinas Inc. | ARVN | Downgrade | Equal Weight (Overweight) |
34.42 (8.01) |
-76.73% | Details | |
| 1/3/2023 | Apellis Pharmaceuticals | APLS | Downgrade | Equal Weight (Overweight) |
51.52 (41.03) |
-20.36% | Details | |
| 10/20/2022 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (N/A) |
|
Details | ||
| 5/31/2022 | Cheniere Energy Partners, LP | CQP | Downgrade | Underweight (Equal Weight) |
55.22 (62.38) |
12.97% | Details | |
| 5/31/2022 | Nurix | NRIX | Upgrade | Overweight (Equal Weight) |
9.02 (23.12) |
156.32% | Details |
